Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Development of semiquantitative ultrasound scoring system to assess cartilage in rheumatoid arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Elevated faecal calprotectin is linked to worse disease status in axial spondyloarthritis: results from the SPARTAKUS cohort

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Secular trends in the incidence and prevalence of gout in Denmark from 1995 to 2015: a nationwide register-based study

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cardiovascular Manifestations of Systemic Sclerosis: A Danish Nationwide Cohort Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Arielle Mendel
  • Sasha Bernatsky
  • Christian A Pineau
  • Yvan St-Pierre
  • John G Hanly
  • Murray B Urowitz
  • Ann E Clarke
  • Juanita Romero-Diaz
  • Caroline Gordon
  • Sang-Cheol Bae
  • Daniel J Wallace
  • Joan T Merrill
  • Jill Buyon
  • David A Isenberg
  • Anisur Rahman
  • Ellen M Ginzler
  • Michelle Petri
  • Mary Anne Dooley
  • Paul Fortin
  • Dafna D Gladman
  • Kristján Steinsson
  • Rosalind Ramsey-Goldman
  • Munther A Khamashta
  • Cynthia Aranow
  • Meggan Mackay
  • Graciela Alarcón
  • Susan Manzi
  • Ola Nived
  • Andreas Jönsen
  • Asad A Zoma
  • Ronald F van Vollenhoven
  • Manuel Ramos-Casals
  • Giuillermo Ruiz-Irastorza
  • Sam Lim
  • Kenneth C Kalunian
  • Murat Inanc
  • Diane L Kamen
  • Christine A Peschken
  • Søren Jacobsen
  • Anca Askanase
  • Jorge Sanchez-Guerrero
  • Ian N Bruce
  • Nathalie Costedoat-Chalumeau
  • Evelyne Vinet
View graph of relations

OBJECTIVES: To assess the prevalence of combined hormonal contraceptives (CHCs) in reproductive-age women with SLE with and without possible contraindications and to determine factors associated with their use in the presence of possible contraindications.

METHODS: This observational cohort study included premenopausal women ages 18-45 years enrolled in the SLICC Registry ⩽15 months after SLE onset, with annual assessments spanning 2000-2017. World Health Organization Category 3 or 4 contraindications to CHCs (e.g. hypertension, aPL) were assessed at each study visit. High disease activity (SLEDAI score >12 or use of >0.5 mg/kg/day of prednisone) was considered a relative contraindication.

RESULTS: A total of 927 SLE women contributed 6315 visits, of which 3811 (60%) occurred in the presence of one or more possible contraindication to CHCs. Women used CHCs during 512 (8%) visits, of which 281 (55%) took place in the setting of one or more possible contraindication. The most frequently observed contraindications were aPL (52%), hypertension (34%) and migraine with aura (22%). Women with one or more contraindication were slightly less likely to be taking CHCs [7% of visits (95% CI 7, 8)] than women with no contraindications [9% (95% CI 8, 10)].

CONCLUSION: CHC use was low compared with general population estimates (>35%) and more than half of CHC users had at least one possible contraindication. Many yet unmeasured factors, including patient preferences, may have contributed to these observations. Further work should also aim to clarify outcomes associated with this exposure.

Original languageEnglish
JournalRheumatology (Oxford, England)
Volume58
Issue number7
Pages (from-to)1259-1267
Number of pages9
ISSN1462-0324
DOIs
Publication statusPublished - 1 Jul 2019

ID: 58902316